CellxLife, a newly established company, aims to revolutionize treatment for children with recurring metastatic Ewing sarcoma and osteosarcoma. The company’s therapeutic dendritic cell-based vaccine technology seeks to provide new and effective options for these young patients.
These aggressive cancers have limited treatment options, with current methods revolving around surgical tumor removal and radiation, followed by chemotherapy. The 5-year survival rate for children with recurrent metastatic disease is typically low, ranging from 20-30%.
CellxLife’s platform harnesses dendritic cells, which are immune cells that present tumor antigens to the immune system. These cells are extracted from the patient, educated using the patient’s tumor cell antigens, and then re-introduced into the body. This process activates immune cells to target residual cancer cells and establishes immunological memory, reducing the risk of recurrence.
Early clinical data has shown promising results. In a Phase 1 study, 75% of pediatric participants with metastatic Ewing’s or osteosarcoma who underwent successful surgery and received the vaccine remained cancer-free today. Notably, 62.5% of participants with metastatic osteosarcoma survived for over 15 years after receiving the therapy.
The clinical team believes the therapy has the potential to treat other solid tumors, including ovarian, breast, colorectal, and pancreatic cancers. The vaccine aims to prevent cancer recurrence after tumor removal by shaping immunological memory.
“This technology has the potential to transform cancer treatment for children,” said Ruvin Orbach, CellxLife’s founder. “With Dr. Eric von Hofe as CEO, we are confident in our ability to advance this promising immunotherapy candidate.”
With his extensive experience in cancer immunotherapy and technology development, Dr. von Hofe brings valuable expertise to CellxLife. The company is dedicated to building a strong team and securing funding to support this innovative therapeutic approach’s further development and clinical trials.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
1 Comment
Eye-Opening Advanced Therapy for Cancer Offers New Hope
10 months ago[…] to interact with and direct the patient’s immune system. These activated macrophages attack cancer cells directly and serve as commanders, orchestrating a broad and coordinated immune response. This […]